A higher number of drugs available as potential treatment options for leukemia means that there has to be increased opportunity for testing, trials and higher patient numbers. Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, talks about the importance of trials and combination drug therapy when treating acute leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
